SLC5A2 and hepatocellular carcinoma: In conclusion, our findings based on a large SEER-Medicare database indicate that HCC patients with pre-existing T2DM treated with SGLT2 inhibitors had significantly lower risk of mortality, especially among those treated more than 12 months.